953 related articles for article (PubMed ID: 29222911)
1. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
3. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
Polyzos SA; Kountouras J; Mantzoros CS
Metabolism; 2019 Mar; 92():82-97. PubMed ID: 30502373
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
6. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.
Rinella ME; Tacke F; Sanyal AJ; Anstee QM;
Hepatology; 2019 Oct; 70(4):1424-1436. PubMed ID: 31287572
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.
Ahmed A; Wong RJ; Harrison SA
Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2062-70. PubMed ID: 26226097
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease: Status Quo.
Sporea I; Popescu A; Dumitrașcu D; Brisc C; Nedelcu L; Trifan A; Gheorghe L; Fierbințeanu Braticevici C
J Gastrointestin Liver Dis; 2018 Dec; 27(4):439-448. PubMed ID: 30574627
[TBL] [Abstract][Full Text] [Related]
10. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
11. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
12. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
[TBL] [Abstract][Full Text] [Related]
13. HSCRP as surrogate marker in predicting long term effect of bariatric surgery on resolution of non-alcoholic steatohepatitis.
Tan CH; Al-Kalifah N; Lee WJ; Ser KH; Lee YC; Chen JC
Asian J Surg; 2019 Jan; 42(1):203-208. PubMed ID: 29804707
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
15. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
Corey KE; Rinella ME
Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
[TBL] [Abstract][Full Text] [Related]
16. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
17. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions.
Campbell P; Symonds A; Barritt AS
Clin Ther; 2021 Mar; 43(3):500-517. PubMed ID: 33583577
[TBL] [Abstract][Full Text] [Related]
18. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Hung CK; Bodenheimer HC
Clin Liver Dis; 2018 Feb; 22(1):175-187. PubMed ID: 29128055
[TBL] [Abstract][Full Text] [Related]
19. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis.
Sayiner M; Lam B; Golabi P; Younossi ZM
Therap Adv Gastroenterol; 2018; 11():1756284818811508. PubMed ID: 30479664
[TBL] [Abstract][Full Text] [Related]
20. Current and future treatment options in non-alcoholic steatohepatitis (NASH).
Lazaridis N; Tsochatzis E
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):357-369. PubMed ID: 28276821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
